| Document |
Document Title |
|
WO/2013/041457A1 |
The invention relates to a N-piperidin-4-yl derivative having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said N-piperidin-4-yl derivatives for...
|
|
WO/2013/036213A1 |
The present invention relates to a pharmaceutical formulation, characterized by comprising a DPP-IV inhibitor and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
|
|
WO/2013/036562A1 |
This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitri
le. The present invention furth...
|
|
WO/2013/036563A1 |
The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitri
le, as the active ingredient in a suitable carrier. The present inventi...
|
|
WO/2013/033283A1 |
Obesity is associated with a state of chronic low-grade inflammation and the present invention establishes that adipose-resident natural killer T (NKT) cells attenuate inflammation in adipose tissue and improves systemic glucose homeosta...
|
|
WO/2013/032012A1 |
[Problem] To provide a glycosylated polypeptide having affinity to somatostatin receptors and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least two amino ...
|
|
WO/2013/032011A1 |
[Problem] To provide a glycosylated polypeptide having an affinity to somatostatin receptors, and, compared to somatostatins, having improved in-blood stability. [Solution] The glycosylated polypeptide is characterized by at least one am...
|
|
WO/2013/023300A1 |
This invention provides compound having a structure of Formula ((IA)/(IB)) or Formula ((IIA)/(IIB)) or Formula (III): Formula (IA) or Formula (IB) or Formula (IIA) (IIB) or (III). Uses of such compounds for treatment of various indicatio...
|
|
WO/2013/023617A1 |
A protein isolated from the Chinese yam Dioscorea opposita that stimulates estrogen and progesterone release in vitro and in vivo but does not stimulate the proliferation of breast and ovarian cancer cells is disclosed. The protein exhib...
|
|
WO/2013/022091A1 |
Provided is a prophylactic, symptom-suppressing, and/or therapeutic agent for autoimmune diseases, which presents little risk of infection and mitigates the burden of administering the drugs to the patient. The prophylactic, symptom-supp...
|
|
WO/2013/020372A1 |
Disclosed by the present invention are methods and reagents for preventing and curing insulin resistance and diabetes mellitus. The present invention also discloses that amyloid-β(Aβ) can induce insulin resistance in peripheral tissues...
|
|
WO/2013/020215A1 |
The use of an aromatase blocker or an estrogen blocker is described in a method for increasing spermatogenesis and Seritolli cell function, and/or improving Leydig cell function, in order to to increase endogenous testosterone levels in ...
|
|
WO/2013/020996A1 |
Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility.
|
|
WO/2013/018675A1 |
The purpose of the present invention is to provide: a compound having an excellent hypoglycemic activity and an excellent activity of protecting β cells or the pancreas, or a pharmaceutically acceptable salt thereof; and a pharmaceutica...
|
|
WO/2013/018733A1 |
A 1,5-naphthyridine derivative represented by general formula [1] (wherein each of R1, R2, R3, R4 and R5 represents a hydrogen atom, an -L-Z group (wherein Z represents a non-aromatic heterocyclic group or the like, and L represents a si...
|
|
WO/2013/018695A1 |
To provide a heterocyclic compound which has an RORγt inhibitory effect. A compound represented by formula (I) or a salt thereof. (In the formula, ring A represents an optionally substituted cyclic group; Q represents a bonding hand or ...
|
|
WO/2013/017374A1 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses th...
|
|
WO/2013/016807A1 |
The present disclosure relates to novel compounds, compositions containing same and methods for treating or preventing a condition associated with a deficient insulin secretion such as diabetes and metabolic syndrome in a subject in need...
|
|
WO/2013/016725A1 |
Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
|
|
WO/2012/123493A9 |
The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprisingthem, combinations and therapeutic uses the...
|
|
WO/2013/014627A1 |
The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modu...
|
|
WO/2013/013273A1 |
The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as met...
|
|
WO/2013/012644A1 |
This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26, 27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydro
xyvitamin D3, and pharmaceutical uses therefor. This compound e...
|
|
WO/2013/011431A1 |
A pharmaceutical composition for topical use for the prophylaxis and treatment of alopecia of different aetiology, and for the stimulation of hair regrowth.
|
|
WO/2013/007167A1 |
The present invention relates to the crystal form I of salt of dipeptidyl peptidase-IV inhibitor and the preparation method and use thereof. In particular, it relates to the crystal form I of dihydrochloride salt of compound (R)-2-[[7-(3...
|
|
WO/2013/008202A1 |
The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusi...
|
|
WO/2013/005755A1 |
A compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (OX) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, d...
|
|
WO/2013/000395A1 |
Disclosed in the present invention is a novel histone deacetylase inhibitor of benzamides and use thereof; the inhibitor has good efficacy in treating diseases caused by abnormal gene expression, such as tumours, endocrine disorders, imm...
|
|
WO/2012/176009A1 |
The present invention relates to the field of treatment and prevention of conditions related to oxidative stress and hormone resistance. Preferably, insulin resistance, and erythropoietin resistance and acetyl-choline resistance are in t...
|
|
WO/2012/175676A2 |
The present invention provides a synthetic peptide molecule that specifically binds an FXYD2-gamma isoform of pancreatic beta cells, said synthetic peptide molecule has 25 amino acids.
|
|
WO/2012/175514A1 |
The present application relates to imidazopyridinone derivatives of the formula (I) as gonadotropin-releasing hormone (GnRH) receptor antagonists. Further aspects of the invention are a process for their preparation and their use for the...
|
|
WO/2012/177215A1 |
The invention relates to a food supplement comprising at least the amino acids leucine, isoleucine, valine, threonine and lysine and Chromium. The invention further relates to food compositions comprising the food supplement as well as u...
|
|
WO/2012/173849A1 |
The present invention provides aldosterone synthase inhibitors of the formula (I): intermediates, methods for their preparation, pharmaceutical preparations, and methods for their use.
|
|
WO/2012/171793A1 |
The present invention relates to a new pharmaceutical product containing an antiprogestin molecule, such as mifepristone (RU486), administered by the nasal route and to be used to modulate the timing of the spontaneous LH surge as part o...
|
|
WO/2012/173184A1 |
[Problem] To provide a LELIA (Liposome-based Enzyme-Linked ImmunoAssay) method using recombinant proteoliposomes, wherein the baseline is sufficiently lowered, allowing the measurement of trace substances that were previously difficult t...
|
|
WO/2012/174359A1 |
Described herein are methods for increasing insulin sensitivity and for treating Diabetes (Type I and Type II). Also described herein are methods for increasing the amount of brown fat in a subject and for treating metabolic disorders, i...
|
|
WO/2012/171065A1 |
The present invention relates to pharmaceutical compositions comprising DITPA, and methods and uses of the pharmaceutical compositions for the treatment for Allan-Herndon-Dudley syndrome including a dosage regime.
|
|
WO/2012/169579A1 |
The invention provides a glycemia elevation inhibitor having a serine protease-inhibiting effect which is a novel therapeutic or prophylactic for diabetes. A compound represented by the following general formula (I) or a pharmaceutically...
|
|
WO/2012/165398A1 |
The present invention relates to a compound having an excellent DGAT inhibitory activity and an anti-feeding activity or a pharmacologically acceptable salt thereof. A compound represented by general formula (I) [wherein R represents a p...
|
|
WO/2012/163932A1 |
The neutralizing prolactin receptor antibody Mat3. and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin rece...
|
|
WO/2012/165314A1 |
The present invention provides an amide compound useful as a therapeutic agent for hypertension and the like. The present invention provides a compound represented by general formula (I) [wherein R1: an optionally substituted adamantyl g...
|
|
WO/2012/164096A1 |
The present invention relates to a process for the preparation of a compound of formula (I) said process comprising the steps of : a) reacting a compound of formula (II), with an acylating or a silylating agent to produce a compound of f...
|
|
WO/2012/162796A1 |
Methods and compositions for enhancing fertility and/or inhibiting pregnancy failure, restoring glucose tolerance and/or preventing glucose intolerance and/or maintaining glucose homeostasis and/or inducing or enhancing weight loss, trea...
|
|
WO/2012/162409A1 |
The present invention is directed to biphenyl derivatives of Formula (I), pharmaceutical compositions containing them and their use in the treatment and / or prevention of disorders and conditions ameliorated by antagonizing one or more ...
|
|
WO/2012/158123A1 |
The present invention relates to a method of treating or preventing insulin resistance syndrome in an animal body by administering an inhibitor of protein kinase RNA-like endoplasmic reticulum kinase (PERK) gene, or a functional variant ...
|
|
WO/2012/156821A1 |
The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a f...
|
|
WO/2012/157746A1 |
The present invention provides a screening method for a preventive or therapeutic agent for an autoimmune disease, comprising evaluating agonist activity or antagonist activity of a test compound on a lysophosphatidylserine receptor usin...
|
|
WO/2012/156822A1 |
The present invention relates to intranasal testosterone gels for the controlled release of testosterone into the systemic circulation of males and females for providing constant effective testosterone blood levels, without inducing unde...
|
|
WO/2012/153729A1 |
The compound represented by formula (IA) or a pharmaceutically acceptable salt thereof is based on orexin (OX)receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxi...
|
|
WO/2012/150676A1 |
Provided are: a composition for inducing the expression of TNFR2, which contains a peptide having a high activity of inducing the expression of TNFR2 as an active ingredient; and a method for producing a cell that expresses TNFR2 in a se...
|
